Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640545 | 1.00 | KDM1A (0.53) | KDM1ABLMPTPN1CA1KDM4C | |
| SCHEMBL5640537 | 1.00 | KDM1A (0.53) | KDM1ABLMPTPN1CA1KDM4C | |
| SCHEMBL7431020 | 0.80 | — | — | |
| SCHEMBL5078045 | 0.78 | TSHR (0.41) | BLMPTPN1 | |
| SCHEMBL10668146 | 0.78 | KDM1A (0.80) | KDM1ABLMPTPN1CA1KDM4C | |
| SCHEMBL10668144 | 0.78 | KDM1A (0.80) | KDM1ABLMPTPN1CA1KDM4C | |
| SCHEMBL7148020 | 0.77 | CES1 (0.44) | PTPN1CA1 | |
| SCHEMBL7148017 | 0.77 | CES1 (0.44) | PTPN1CA1 | |
| SCHEMBL7148023 | 0.77 | CES1 (0.44) | PTPN1CA1 | |
| SCHEMBL11741773 | 0.76 | KDM1A (0.53) | KDM1ABLMPTPN1CA1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189851-B2 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | CALCRL, CALCR, CALCB | KDM1A 4842/4885BLM 519/4885PTPN1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.